BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15739264)

  • 21. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
    Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
    Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin.
    Hsu HC; Chang HK; Lin YC; Hseu S; Chen JS; Yang TS; Wang HM; Shen WC
    Chang Gung Med J; 2009; 32(1):33-41. PubMed ID: 19292937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.
    Pichon MF; Hacene K; Guepratte S; Neumann R
    Clin Lab; 2004; 50(3-4):163-70. PubMed ID: 15074470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of long-term (5-year) survival in patients with metastatic breast cancer to the liver].
    Kan N
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1780-4. PubMed ID: 17212106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 gene status in primary breast cancers and matched distant metastases.
    Tapia C; Savic S; Wagner U; Schönegg R; Novotny H; Grilli B; Herzog M; Barascud AD; Zlobec I; Cathomas G; Terracciano L; Feichter G; Bubendorf L
    Breast Cancer Res; 2007; 9(3):R31. PubMed ID: 17511881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
    Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum big endothelin-1 levels in female patients with breast cancer.
    Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
    Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
    Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
    Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype].
    Gerson R; Alban F; Villalobos A; Serrano A
    Gac Med Mex; 2008; 144(1):27-34. PubMed ID: 18619055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pattern of metastatic spread in triple-negative breast cancer.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.